Approval Package for:

APPLICATION NUMBER:

207795Orig1s000

Trade Name: Vyzulta, 0.024%

Generic or Proper Name: latanoprostene bunod ophthalmic solution

Sponsor: Bausch & Lomb Inc

Approval Date: November 2, 2017

Indication: For reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
**CONTENTS**

<table>
<thead>
<tr>
<th>Reviews / Information Included in this NDA Review.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
</tr>
<tr>
<td>Other Action Letters</td>
</tr>
<tr>
<td>Labeling</td>
</tr>
<tr>
<td>REMS</td>
</tr>
<tr>
<td>Summary Review</td>
</tr>
<tr>
<td>Officer/Employee List</td>
</tr>
<tr>
<td>Office Director Memo</td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
</tr>
<tr>
<td>Clinical Review(s)</td>
</tr>
<tr>
<td>Product Quality Review(s)</td>
</tr>
<tr>
<td>Non-Clinical Review(s)</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
</tr>
<tr>
<td>Clinical Microbiology / Virology Review(s)</td>
</tr>
<tr>
<td>Clinical Pharmacology Review(s)</td>
</tr>
<tr>
<td>Other Reviews</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
</tr>
</tbody>
</table>
NDA 207795

Bausch & Lomb Inc.
Attention: Mary Harrell, BsBM, RAC
   Senior Director, Regulatory Affairs
400 Somerset Corporate Boulevard
Bridgewater, NJ 08807

Dear Ms. Harrell:

Please refer to your New Drug Application (NDA) dated July 21, 2015, received July 21, 2015, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%. We acknowledge receipt of your amendment dated August 17, 2017, which constituted a complete response to our August 7, 2017, action letter.

This new drug application provides for the use of Vyzulta (latanoprostene bunod ophthalmic solution), 0.024% for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(b)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text for the package insert. Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.
CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 207795**." Approval of this submission by FDA is not required before the labeling is used.

ADVISORY COMMITTEE

Your application for Vyzulta (latanoprostene bunod ophthalmic solution), 0.024% was not referred to an FDA advisory committee because there were no controversial issues that would benefit from advisory committee discussion and outside expertise was not necessary.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable. We are waiving the pediatric study requirement for this application because there are too few patients with the disease/condition to study.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert, Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:  

Reference ID: 4175996
As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

If you have any questions, call Lois Almoza, M.S., Regulatory Project Manager, at (301) 796-1600.

Sincerely,

{See appended electronic signature page}

John Farley, M.D., M.P.H.
Deputy Director
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosures:
Content of Labeling
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOHN J FARLEY
11/02/2017